US equities
|
NVDA
$239.24
▲+0.14%
MU
$1,045.56
▼-1.73%
SPCX
$171.92
▲+0.49%
AMD
$649.42
▲+2.80%
MRVL
$287.01
▲+5.81%
AVGO
$375.81
▲+3.67%
INTC
$112.50
▼-3.18%
MSFT
$529.30
▲+0.78%
NVDA
$239.24
▲+0.14%
MU
$1,045.56
▼-1.73%
SPCX
$171.92
▲+0.49%
AMD
$649.42
▲+2.80%
MRVL
$287.01
▲+5.81%
AVGO
$375.81
▲+3.67%
INTC
$112.50
▼-3.18%
MSFT
$529.30
▲+0.78%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Axim Biotechnologies Inc
(OP:
AXIM
)
0.0035
+0.0001 (+2.94%)
Delayed Quote
Updated: 3:30 PM EDT, Oct 6, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Axim Biotechnologies Inc
< Previous
1
2
Next >
AXIM® Biotechnologies Receives Initial Order for Diagnostic Solutions as Exclusive Partner Verséa Ophthalmics Commences Initial Commercial Launch
October 04, 2022
Healthcare Solutions Company Receives Initial Order for Ophthalmic Diagnostic Tests and Readers, Marking First Large Revenue Generating Order for Company
From
AXIM BIOTECHNOLOGIES, INC
Via
GlobeNewswire
AXIM® Biotechnologies Point-of-Care Diagnostic Test Platform Sales Commence With Verséa Ophthalmics’ Commercial Launch at AAO 2022
September 29, 2022
Sales of Point-of-Care Diagnostic Tests for Ocular Surface Disease Commence at the American Academy of Ophthalmology Annual Meeting Through Exclusive Partnership
From
AXIM BIOTECHNOLOGIES, INC
Via
GlobeNewswire
AXIM Biotechnologies Enhances IgE Testing Capabilities; Responds to Global Warming's Impact on Allergy Season
July 26, 2022
From
AXIM BIOTECHNOLOGIES, INC
Via
GlobeNewswire
Will This Dry Eye Rapid Test Prove To Be A Rapid Success?
↗
July 07, 2022
During the last few years of the COVID-19 pandemic, the term “rapid test” conjures images of overlong cotton swabs reaching heretofore untouched corners of nasal cavities. In reality, rapid tests aid...
Via
Benzinga
Medical Marijuana, Inc. Reports Revenue Of $7.8M For Q1 2022
↗
May 19, 2022
Medical Marijuana, Inc. (OTCPK:MJNA) released its financial results for the quarter ending March 31, 2022, revealing $7.8 million in net revenue, a 24% increase when compared to the previous quarter....
Via
Benzinga
< Previous
1
2
Next >